E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 7/11/2006 in the Prospect News Biotech Daily.

Beckman at outperform by RBC

RBC Capital Markets analyst William R. Quirk rated Beckman Coulter, Inc. at outperform, above average risk, in a preview of the company's second-quarter 2006 results. The analyst is expecting in-line results, although the company could deliver slightly better-than-expected operating income, although currency based. Overall, results should strengthen as the year progresses. Shares of the Fullerton, Calif.-based biomedical company were up 16 cents, or 0.28%, at $56.44 on volume of 206,600 shares versus the three-month running average of 532,921 shares. (NYSE: BEC)


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.